Drug Profile
Research programme: bispecific therapeutics - Exscientia/Sanofi
Latest Information Update: 23 Aug 2022
Price :
$50
*
At a glance
- Originator Exscientia
- Developer Exscientia; Sanofi
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Immunological disorders
- No development reported Metabolic disorders
Most Recent Events
- 23 Aug 2022 Early research is still ongoing for immunological disorders in France and United Kingdom
- 07 Jan 2022 Exscientia and Sanofi enter into a research collaboration with a licensing option to develop small molecule candidates across oncology and immunology
- 07 Jan 2022 Early research in Cancer in France (unspecified route)